Acadia Pharmaceuticals vs Ascendis Pharma A/S
ACAD and ASND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and ASND compare
Ascendis Pharma A/S grew revenue faster over the last twelve months (113% versus 11.8% for Acadia Pharmaceuticals).
Ascendis Pharma A/S keeps more of each dollar of sales as profit, with a net margin of 70.8% compared with 33.4% at Acadia Pharmaceuticals.
Acadia Pharmaceuticals scores higher on the StockData Score (15 against 7 for Ascendis Pharma A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | ASND |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | – |
| Share price | $20.59 | $251.27 |
| Change, 1 year | −8.6% | 22.1% |
| Change, 5 years | 2.8% | 56.4% |
| Beta (5Y) | 0.82 | 0.77 |
| Employees | 798 | 879 |
| StockData Score | ||
| Total score | 15 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 9.3× | – |
| P/S | 3.1× | – |
| P/B | 2.7× | – |
| EV/EBITDA | 30.0× | – |
| P/FCF | 24.4× | – |
| FCF yield | 4.1% | – |
| Fair value | $24.98 | – |
| Margin of safety | 17.6% | – |
| Growth | ||
| Revenue growth (TTM) | 11.8% | 113% (better) |
| Revenue growth, 5Y average | 19.4% | 153% (better) |
| Net income growth (TTM) | 71.3% | – |
| EPS growth (TTM) | 66.2% | – |
| Profitability | ||
| Gross margin | 91.1% | 91.3% (better) |
| Operating margin | 7.6% | 25.4% (better) |
| Net margin | 33.4% | 70.8% (better) |
| FCF margin | 12.8% | – |
| Return on equity | 35.7% | – |
| Return on invested capital | 42.1% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | −1.61 |
| Interest coverage | – | 1.3× |
| Current ratio | 3.39 (better) | 2.99 |
| Altman Z-score | 4.86 | – |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | −1.3% | – |
| Shareholder yield | −1.3% | – |
| Ownership | ||
| Held by institutions | 97.9% | 108% |
| Held by insiders | 27.8% | 0.83% |
| Insider net buying, 12 months | −$3.4M (better) | −$4.7M |
| Short interest, % of float | 6.7% | – |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- ASND stock overview
- ASND income statement
- ASND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.